TherapeuticsMD, Inc.
TXMD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $2 | $1 | $70 | $3 |
| % Growth | 35.3% | -98.1% | 2,619.1% | – |
| Cost of Goods Sold | $0 | $0 | $1 | $1 |
| Gross Profit | $2 | $1 | $69 | $1 |
| % Margin | 100% | 100% | 98% | 45.5% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $58 | $73 |
| SG&A Expenses | $0 | $0 | $57 | $73 |
| Sales & Mktg Exp. | $0 | $0 | -$1 | $0 |
| Other Operating Expenses | $7 | $10 | $11 | $8 |
| Operating Expenses | $7 | $10 | $67 | $81 |
| Operating Income | -$5 | -$9 | $1 | -$80 |
| % Margin | -270.3% | -654.6% | 1.7% | -3,092.8% |
| Other Income/Exp. Net | $2 | $1 | -$0 | $0 |
| Pre-Tax Income | -$2 | -$8 | $1 | -$79 |
| Tax Expense | -$0 | -$0 | $0 | $0 |
| Net Income | -$2 | -$10 | $112 | -$172 |
| % Margin | -123.9% | -789.4% | 160.1% | -6,700.9% |
| EPS | -0.19 | -0.55 | -10.35 | -25.83 |
| % Growth | 65.5% | 94.7% | 59.9% | – |
| EPS Diluted | -0.19 | -0.74 | -10.35 | -25.83 |
| Weighted Avg Shares Out | 12 | 10 | 9 | 8 |
| Weighted Avg Shares Out Dil | 12 | 10 | 9 | 8 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $33 |
| Depreciation & Amortization | $1 | $0 | $1 | $1 |
| EBITDA | -$3 | -$8 | $12 | -$71 |
| % Margin | -169.4% | -620.9% | 17% | -2,753.2% |